Mezavant (Mesalazine)

Mesalazine exerts its effect locally in the intestinal mucosa. It blocks cyclooxygenase and lipoxygenase enzymes, decreasing prostaglandin and leukotriene production, and acts as a free‑radical scavenger. These actions collectively reduce inflammatory mediators and help restore normal colonic tissue.

The dosage of Mezavant is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Healthcare professionals determine the appropriate strength, frequency, and duration of treatment according to current clinical guidelines.

The safety of Mezavant in pregnancy and lactation has not been definitively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To order Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant delivers mesalazine directly to the colon via a delayed‑release formulation, offering targeted anti‑inflammatory action. Compared with sulfasalazine, it lacks the sulfapyridine component, reducing certain systemic side effects. Biologic agents act systemically and are reserved for moderate‑to‑severe disease, whereas Mezavant is typically used for mild‑to‑moderate cases.

Store Mezavant tablets at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the packaging tightly closed and out of reach of children. Do not store in high‑heat environments such as car trunks or near radiators.

Mezavant is taken orally as a delayed‑release tablet. Swallow the tablet whole with a full glass of water; do not crush, chew, or split it, as this can compromise the coating that ensures release in the colon. Follow the prescribing clinician’s instructions regarding timing and food intake.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury manifested by elevated transaminases, acute pancreatitis, and blood disorders like neutropenia or agranulocytosis. Patients should seek immediate medical attention if they develop rash, jaundice, abdominal pain, or unexplained fever.

Mezavant is contraindicated in individuals with known hypersensitivity to mesalazine or other salicylates. It should be used with caution, or avoided, in patients with severe renal or hepatic impairment, and is not recommended for children unless specifically prescribed by a pediatric gastroenterologist.